Dose Adjustment of Biologic Treatments for Moderate-to-Severe Plaque Psoriasis in the Real World: A Systematic Review.
Adalimumab
Dosing
Etanercept
Infliximab
Plaque psoriasis
Secukinumab
Ustekinumab
Journal
Dermatology and therapy
ISSN: 2193-8210
Titre abrégé: Dermatol Ther (Heidelb)
Pays: Switzerland
ID NLM: 101590450
Informations de publication
Date de publication:
Aug 2021
Aug 2021
Historique:
received:
12
04
2021
pubmed:
4
6
2021
medline:
4
6
2021
entrez:
3
6
2021
Statut:
ppublish
Résumé
Dose escalation and reduction of biologic treatments are frequent in clinical practice. The aim of this systematic review is to summarise evidence on dose adjustment of biologic treatments for moderate-to-severe plaque psoriasis in the real-world. A systematic review of real-world evidence on dose adjustment of biologics for plaque psoriasis was performed. Searches were conducted in BIOSIS Previews The search identified 162 papers, and 20 studies with 30,912 patients were included from 2014 to 2020. More studies reported on dose escalation than dose reduction. For adalimumab, 3-54% of patients had dose reduction while 0-37% had dose escalation. For infliximab, only two studies reported a dose reduction, with rates of 22-29%, while dose escalation rates varied from 14 to 67%. Dose reduction rates of 5-49% were reported for etanercept while 0-55% of patients had doses escalated. For ustekinumab, dose escalation and reduction rates ranged from 3 to 37% and 7 to 42%, respectively. Two studies reported on dose adjustment for secukinumab; in one 52% of patients initiated on 150 mg instead of the recommended 300 mg, while another reported no dose increase. Dose adjustment of biologics for psoriasis is common, with escalation more frequently reported than reduction. Dose escalation may have economic and safety consequences, while dose reduction may impact efficacy. These aspects are important to consider when making decisions on treatment dosing.
Identifiants
pubmed: 34081304
doi: 10.1007/s13555-021-00559-z
pii: 10.1007/s13555-021-00559-z
pmc: PMC8322248
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
1141-1156Informations de copyright
© 2021. The Author(s).
Références
Armstrong AW, Puig L, Joshi A, et al. Comparison of biologics and oral treatments for plaque psoriasis: a meta-analysis. JAMA Dermatol. 2020;156(3):258–69.
doi: 10.1001/jamadermatol.2019.4029
Sbidian E, Chaimani A, Afach S, et al. Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis. Cochrane Database Syst Rev. 2020;1(1):CD011535. https://doi.org/10.1002/14651858.CD011535.pub3 (Update in: Cochrane Database Syst Rev. 2021 Apr 19;4:CD011535).
doi: 10.1002/14651858.CD011535.pub3
pubmed: 31917873
Lebwohl M, Strober B, Menter A, et al. Phase 3 studies comparing brodalumab with ustekinumab in psoriasis. N Engl J Med. 2015;373(14):1318–28.
doi: 10.1056/NEJMoa1503824
Thaçi D, Blauvelt A, Reich K, et al. Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial. J Am Acad Dermatol. 2015;73(3):400–9.
doi: 10.1016/j.jaad.2015.05.013
Blauvelt A, Papp KA, Griffiths CE, et al. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: Results from the phase III, double-blinded, placebo- and active comparator-controlled VOYAGE 1 trial. J Am Acad Dermatol. 2017;76(3):405–17.
doi: 10.1016/j.jaad.2016.11.041
Reich K, Armstrong AW, Foley P, et al. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: results from the phase III, double-blind, placebo- and active comparator-controlled VOYAGE 2 trial. J Am Acad Dermatol. 2017;76(3):418–31.
doi: 10.1016/j.jaad.2016.11.042
Carrascosa JM, Garcia-Doval I, Pérez-Zafrilla B, et al. Use of off-label doses is frequent in biologic therapy for moderate to severe psoriasis: a cross-sectional study in clinical practice. J Dermatolog Treat. 2015;26:502–6.
doi: 10.3109/09546634.2015.1034070
Iskandar IYK, Ashcroft DM, Warren RB, et al. Patterns of biologic therapy use in the management of psoriasis: cohort study from the British Association of Dermatologists Biologic Interventions Register (BADBIR). Br J Dermatol. 2017;176:1297–307.
doi: 10.1111/bjd.15027
Esposito M, Gisondi P, Conti A, et al. Dose adjustment of biologic therapies for psoriasis in dermatological practice: a retrospective study. J Eur Acad Dermatol Venereol. 2017;31:863–9.
doi: 10.1111/jdv.14145
Brezinski EA, Armstrong AW. Off-label biologic regimens in psoriasis: a systematic review of efficacy and safety of dose escalation, reduction, and interrupted biologic therapy. PLoS ONE. 2012;7(4):e33486. https://doi.org/10.1371/journal.pone.0033486 .
doi: 10.1371/journal.pone.0033486
pubmed: 22509259
pmcid: 3324468
Smith CH, Yiu ZZN, Bale T, et al. British Association of Dermatologists guidelines for biologic therapy for psoriasis 2020: a rapid update. Br J Dermatol. 2020. https://doi.org/10.1111/bjd.19039 .
doi: 10.1111/bjd.19039
pubmed: 33316094
pmcid: 7267275
Bewley A, Miglio C, Tian H, Gilloteau I, Whitehead J, Hermans R. Dose increase beyond labelled dose of biologics is associated with incremental pharmacy costs: results from a real-world study in the UK. J Dermatolog Treat. 2019;30:376–82.
doi: 10.1080/09546634.2018.1524820
Cai Q, Carter C, AbuDagga A, Schenkel B, Jones M, Tan H. Real-world dosing and utilization of ustekinumab among patients with psoriasis. Am J Pharm Benefits. 2014;6(3):129–36.
Cao Z, Carter C, Wilson KL, Schenkel B. Ustekinumab dosing, persistence, and discontinuation patterns in patients with moderate-to-severe psoriasis. J Dermatolog Treat. 2015;26:113–20.
doi: 10.3109/09546634.2014.883059
Carter C, Wilson KL, Smith D, Lee S. Comparative treatment patternsamong psoriasis patients using adalimumab, etanercept, or ustekinumab. Am J Pharm Benefits. 2016;8:191–8.
Egeberg A, Ottosen MB, Gniadecki R, et al. Safety, efficacy and drug survival of biologics and biosimilars for moderate-to-severe plaque psoriasis. Br J Dermatol. 2018;178:509–19.
doi: 10.1111/bjd.16102
Esposito M, Prignano F, Rongioletti F, et al. Efficacy and safety of adalimumab after failure of other anti-TNFα agents for plaque-type psoriasis: clinician behavior in real life clinical practice. J Dermatolog Treat. 2019;30:441–5.
doi: 10.1080/09546634.2018.1529382
Feldman SR, Zhao Y, Navaratnam P, Friedman HS, Lu J, Tran MH. Patterns of medication utilization and costs associated with the use of etanercept, adalimumab, and ustekinumab in the management of moderate-to-severe psoriasis. J Manag Care Spec Pharm. 2015;21:201–9.
pubmed: 25726029
Feldman SR, Zhao Y, Zhou H, Herrera V, Tian H, Li Y. Economic impact of above-label dosing with etanercept, adalimumab, or ustekinumab in patients with psoriasis. J Manag Care Spec Pharm. 2017;23:583–9.
pubmed: 28448778
Gulliver WP, Randell S, Gulliver S, Gregory V, Nagle S, Chambenoit O. Biologic therapy utilization in patients with moderate to severe psoriasis and psoriatic arthritis: an observational summary of biologic therapy use in a clinical setting. J Cutan Med Surg. 2018;22:567–76.
doi: 10.1177/1203475418786712
Lee EB, Thomas LW, Vegeberg A, Wu JJ. Dosage adjustments in patients with psoriasis on etanercept: a retrospective chart review. J Psoriasis Psoriatic Arthritis. 2020;5:52–3.
doi: 10.1177/2475530320910466
Luber AJ, Tsui CL, Heinecke GM, Lebwohl MG, Levitt JO. Long-term durability and dose escalation patterns in infliximab therapy for psoriasis. J Am Acad Dermatol. 2014;70:525–32.
doi: 10.1016/j.jaad.2013.10.059
Romero-Jimenez RM, Escudero-Vilaplana V, Baniandres Rodriguez O, García Martín E, Mateos Mayo A, Sanjurjo SM. Association between clinical factors and dose modification strategies in the treatment with ustekinumab for moderate-to-severe plaque psoriasis. J Dermatolog Treat. 2018;29:792–6.
doi: 10.1080/09546634.2018.1466978
Sanz-Gil R, Pellicer A, Montesinos MC, Valcuende-Cavero F. Improved effectiveness from individualized dosing of self-administered biologics for the treatment of moderate-to-severe psoriasis: a 5-year retrospective chart review from a Spanish University Hospital. J Dermatolog Treat. 2020;31:370–7.
doi: 10.1080/09546634.2019.1602246
Schwensen JF, Clemmensen A, Sand C, et al. Effectiveness and safety of secukinumab in 69 patients with moderate to severe plaque psoriasis: a retrospective multicenter study. Dermatol Ther. 2017. https://doi.org/10.1111/dth.12550 .
doi: 10.1111/dth.12550
pubmed: 28906051
Wilder EG, Patel M, Hebeler K, Menter A. Ustekinumab treatment for psoriasis in 119 patients maintained on therapy for a minimum of one year: a review. J Drugs Dermatol. 2014;13:905–10.
pubmed: 25116966
Wu JJ, Guérin A, Gauthier G, Sundaram M. Healthcare resource utilization, healthcare costs and dose escalation in psoriasis patients initiated on ustekinumab versus adalimumab: a retrospective claim study. J Dermatolog Treat. 2017;28:290–8.
doi: 10.1080/09546634.2016.1247946
Zweegers J, Groenewoud JMM, van den Reek JMPA, et al. Comparison of the 1- and 5-year effectiveness of adalimumab, etanercept and ustekinumab in patients with psoriasis in daily clinical practice: results from the prospective BioCAPTURE registry. Br J Dermatol. 2017;176:1001–9.
doi: 10.1111/bjd.15023
Llamas-Velasco M, Daudén E. Reduced doses of biological therapies in psoriasis may increase efficiency without decreasing drug survival. Dermatol Ther. 2020;33(6):e14134.
pubmed: 32761730
Al-Hammadi A, Ruszczak Z, Magariños G, Chu CY, El Dershaby Y, Tarcha N. Intermittent use of biologic agents for the treatment of psoriasis in adults. J Eur Acad Dermatol Venereol. 2020. https://doi.org/10.1111/jdv.16803.10.1111/jdv.16803 .
doi: 10.1111/jdv.16803.10.1111/jdv.16803
pubmed: 32639047
Membrive Jiménez C, Pérez Ramírez C, Sánchez Martín A, et al. Influence of genetic polymorphisms on response to biologics in moderate-to-severe psoriasis. J Pers Med. 2021;11(4):293.
doi: 10.3390/jpm11040293
Ovejero-Benito MC, Reolid A, Sánchez-Jiménez P, et al. Histone modifications associated with biological drug response in moderate-to-severe psoriasis. Exp Dermatol. 2018;27(12):1361–71.
doi: 10.1111/exd.13790